What Qron does

Based on the available source material, the entity branded "Qron" presents materially conflicting identities across data blocks. The firmographics layer describes Qron as a publicly-traded (OTCQB: QRON), preclinical biotechnology company founded in 2016, headquartered in New York, developing cell-based therapeutics for neurological injuries, with a leadership team of CEO Jonah Meer and Co-Founder/President Ido Merfeld. However, primary-source web content for qron.com shows the domain being marketed for sale by Grails.com as a "strategic-grade" premium digital asset, with no operating business, products, or technology behind it. A separate data block refers to "Qrons / First Person" preparing for a Regulation A offering from a private structure, and notes that no public listing or ticker has been independently verified. Financial line items (operating losses in the hundreds of billions, multi-trillion-dollar enterprise values) are internally inconsistent with a 1–10 employee organization and are treated as unreliable.

The only documented "product" across all sources is the qron.com domain name itself. No biotech pipeline, clinical assets, manufacturing capability, R&D footprint, or commercial infrastructure is described. Headcount is 1–10, the sole funding event on file is a $500,000 raise in February 2018 from undisclosed investors, and pricing is explicitly undisclosed due to a development/pre-Reg A stage. There are no named customers, no partnerships, no certifications, no regulatory actions, and no M&A activity on record.

Taken together, the evidence supports describing Qron as a very small, pre-revenue entity whose principal identifiable asset is the qron.com domain, with a contradictory biotech narrative in firmographic data that is not corroborated by operating, product, technology, financial, or customer evidence in any other source. Investors should treat the biotech positioning as unverified pending primary-source confirmation of pipeline, capital structure, and operating status.

Name

Qron

Website

https://qron.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Qron is a 1–10 employee entity whose principal identifiable asset is the qron.com premium domain name listed for sale via Grails.com; firmographic data also describes a preclinical biotech on OTCQB, but this positioning is not corroborated by any product, technology, customer, or financial evidence in the source material.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Marketing or Sales, Others

Core offering

Qron offers QRON.COM, a strategic-grade internet domain name positioned as a premium digital asset for established businesses and funded startups. The domain is marketed not for creativity or availability but for alignment with long-term business strategy, reducing friction in execution and communication, and strengthening brand positioning. The asset is available for sale or other proposals through Grails.com.

Product overview

Qron operates as a single offering—QRON.COM, a strategic-grade domain name available for sale. The domain is marketed as a premium digital asset for established businesses and funded startups, designed to provide strategic value through brand alignment and long-term positioning rather than creativity or availability. No additional products, modules, or platform components are described in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

• QRON.COM Domain Name A strategic-grade internet domain name offered for sale or other proposals. Marketed as a premium digital asset for established businesses and funded startups, delivering value through brand alignment, reduced execution friction, and long-term positioning rather than creativity or availability. Listed and brokered via Grails.com.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• BrainStorm Cell Therapeutics: Clinical-stage cell-therapy company focused on neurodegenerative diseases (e.g., ALS, MS). Closest comparable to the firmographic description of Qron as a preclinical cell-therapy company developing treatments for neurological injuries.
• Lineage Cell Therapeutics: Clinical-stage cell-therapy company developing allogeneic cell transplants for neurological and ophthalmologic conditions. Directly comparable business model (publicly traded, cell-based, neurological indications).
• Athersys: Clinical-stage biotech developing cell-therapy treatments for neurological injury (notably MultiStem for stroke and trauma). Closely comparable therapeutic focus area to Qron's described neurological-injury indication.
• Pluristem Therapeutics: Cell-therapy company developing placenta-derived cell therapies for multiple indications including neurological conditions. Comparable as a small-cap publicly listed cell-therapy peer with limited operating capacity similar to Qron's profile.
• Cytori Therapeutics: Cell-therapy company developing autologous cell therapies for soft tissue and neurological injuries. Highly comparable therapeutic focus on cell-based solutions for injuries.

Emerging players

• International Stem Cell Corporation: Small-cap cell-therapy biotech focused on regenerative medicine and neurological disease. Comparable scale and stage profile to a preclinical public cell-therapy company.
• Neuralstem: Small public biotech historically focused on neural cell-based therapeutics for CNS injuries and diseases. Comparable as a low-resource public peer in the cell-therapy-for-neurology niche.

Others

• Sedo: Major domain aftermarket and brokerage. Comparable as an infrastructure enabler for the actual observed business activity (selling the QRON.COM domain) rather than the firmographic biotech description.
• Afternic (GoDaddy): Large-scale domain resale marketplace. Comparable to the actual observed function of QRON.COM's listing as a digital asset being offered for sale through a brokerage.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/qrons

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qron